Cell line · CVCL_0095
Papers35
1 to 20 of 35
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| A Drug-Gated, Modular STAb-T Immunotherapy With External Control. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| BCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| IGF2BP3 redirects glycolytic flux to promote one-carbon metabolism and RNA methylation. | Cell Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Enhancing Anti-Tumor Effects of Engineered Extracellular Vesicles via Endocytosis Route Switching and Interferon Response Suppression. | Adv Sci (Weinh) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Systematic Evaluation of GAPs and GEFs Identifies a Targetable Dependency for Hematopoietic Malignancies. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Effectorless Fc-fusion improves FLT3L drug-like properties for cancer immunotherapy combinations. | EBioMedicine | 2025 | Its Methods give the RRID and name the line | PubMed | |
| DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. | Blood Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Highly specific Immunoproteasome inhibitor M3258 induces proteotoxic stress and apoptosis in KMT2A::AFF1 driven acute lymphoblastic leukemia. | Sci Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| KMT2A degradation is observed in decitabine-responsive acute lymphoblastic leukemia cells. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Epigenomic mapping reveals distinct B cell acute lymphoblastic leukemia chromatin architectures and regulators. | Cell Genom | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Functional Characterization of Transforming Growth Factor-β Signaling in Dasatinib Resistance and Pre-BCR+ Acute Lymphoblastic Leukemia. | Cancers (Basel) | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Siglec-15 Promotes Evasion of Adaptive Immunity in B-cell Acute Lymphoblastic Leukemia. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model. | Oncotarget | 2022 | Its Methods give the RRID and name the line | PubMed | |
| hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia. | Cell Rep Med | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines. | Nat Commun | 2022 | Cellosaurus cites it | PubMed | |
| Capture-C: a modular and flexible approach for high-resolution chromosome conformation capture. | Nat Protoc | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Functional interrogation of HOXA9 regulome in MLLr leukemia via reporter-based CRISPR/Cas9 screen. | Elife | 2020 | Its Methods give the RRID and name the line | PubMed | |
| Quantitative Proteomics of the Cancer Cell Line Encyclopedia. | Cell | 2020 | Cellosaurus cites it | PubMed | |
| CPSF3-dependent pre-mRNA processing as a druggable node in AML and Ewing's sarcoma. | Nat Chem Biol | 2020 | Its Methods give the RRID and name the line | PubMed | |
| The LL-100 panel: 100 cell lines for blood cancer studies. | Sci Rep | 2019 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0095/papers